Login to Your Account

Financings Roundup

Friday, May 6, 2011
Oncothyreon Inc., of Seattle, said the underwriters of its recently completed $40 million public stock offering fully exercised their overallotment option, boosting the gross proceeds to $46 million. Net proceeds of $43 million will support Oncothyreon's Phase I and Phase II cancer pipeline.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription